The safety of nonsteroidal anti-inflammatory drugs in population-based studies: the benefits of aceclofenac

Effective pain relief in rheumatology practice is one of the most important criteria for the quality of medical care. Therefore, drugs with analgesic effects, primarily nonsteroidal anti-inflammatory drugs (NSAIDs), are among the most commonly used ones in the combination therapy of rheumatic diseases. All NSAIDs are capable of causing to one degree or another extent unwanted reactions that occur in the gastrointestinal tract (GIT), cardiovascular system (CVS), liver, kidneys, and allergic reactions. Considering the widespread use of NSAIDs, the problem of preventing these complications becomes not only medical, but also social.
In 2008, the European Union launched the international project SOS (Safety Of non-Steroidal anti-inflammatory drugs) to study the safety of NSAIDs. The results of this project have shown that aceclofenac is one of the most successful drugs in combining the safety for GIT and CVS. Compared with other NSAIDs, this drug has a minimal risk for GI bleeding (relative risk (RR) 1.43; 95% confidence interval (CI), 0.65–3.15); it does not increase the risk of hospitalization for heart failure (RR, 1.03; 95% CI, 0.91–1.15) or the risk of developing myocardial infarction (RR 1.04; 95% CI, 0.90–1.19) either. The risk of ischemic stroke during aceclofenac therapy was slightly increased (RR, 1.17); but statistically insignificant (95% CI, 0.98–1.39).
A large number of randomized clinical trials, meta-analyses, and observational programs have demonstrated that aceclofenac has pronounced analgesic and anti-inflammatory effects that are comparable to those of other NSAIDs and can be used in diseases accompanied by musculoskeletal pain, including that in older patients.

nonsteroidal anti-inflammatory drugs, aceclofenac, GIT bleeding, myocardial infarction, ischemic stroke, heart failure, relative risk of complications

1. Chua JR, Gibson KA, Pincus T. Pain and other self-report scores in patients with osteoarthritis indicate generally similar disease burden to patients with rheumatoid arthritis. Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):88-93. Epub 2017 Sep 28.

2. Ten Klooster PM, Veehof MM, Taal E, et al. Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. Ann Rheum Dis. 2007 Nov;66(11):1485-90. doi: 10.1136/ard.2007.069765. Epub 2007 May 1.

3. Nasonov EL, editor. Klinicheskie rekomendatsii. Revmatologiya [Clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. P. 349-55.

4. Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-24. (In Russ.). doi: 10.14412/1996-7012-2015-1-4-23

5. Arrais PSD, Fernandes MEP, Pizzol T, et al. Prevalence of self-medication in Brazil and associated factors. Rev Saude Publica. 2016 Dec;50(suppl 2):13s. doi: 10.1590/S1518-8787.2016050006117.

6. Zhou Y, Boudreau DM, Freedman AN. Trends in the use of aspirin and nonsteroidal anti-inflammatory drugs in the general U.S. population. Pharmacoepidemiol Drug Saf. 2014 Jan;23(1):43- 50. doi: 10.1002/pds.3463.

7. Kasciuskevisiü te S, Gumbrevicius G, Vendzelyte A, et al. Impact of the World Health Organization Pain Treatment Guidelines andthe European Medicines Agency Safety Recommendations on Nonsteroidal Anti-Inflammatory Drug Use in Lithuania: An Observational Study. Medicina (Kaunas). 2018 May 11;54(2):30. doi: 10.3390/medicina54020030.

8. Lindsley CW. 2014 Global Prescription Medication Statistics: Strong Growth and CNS Well Represented. ACS Chem Neurosci. 2015 Apr 15;6(4):505-6. doi: 10.1021/acschemneuro.5b00098

9. Lindsley CW. 2015: A New Impact Factor for ACS Chemical Neuroscience and New Topline Data for Global Pharmaceutical Products. ACS Chem Neurosci. 2016 Jul 20; 7(7):842-3. doi: 10.1021/acschemneuro.6b00177.

10. Medicines Use and Spending in the U.S. https://www.iqvia.com/institute/reports/medicines-use-and-spending-in-the-us-a-reviewof-2016

11. Paulose-Ram R, Hirsch R, Dillon C, et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003 Jun; 12(4):315-26. doi: 10.1002/pds.755.

12. Sarganas G, Buttery AK, Zhuang W, et al. Prevalence, trends, patterns and associations of analgesic use in Germany. BMC Pharmacol Toxicol. 2015 Oct 1;16:28. doi: 10.1186/s40360-015-0028-7.

13. Samuelsen P, Sl∅rdal L, Mathisen UD, et al. Analgesic use in a Norwegian general population: change over time and high-risk use – The Troms∅ Study. BMC Pharmacol Toxicol. 2015 Jun 6;16:16. doi: 10.1186/s40360-015-0016-y.

14. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000.

15. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857.

16. Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.

17. Masclee GMC, Straatman H, Arfe A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.

18. Peris F, Bird HA, Srni U, et al. Treatment compliance and safety of aceclofenac versus standart NSAIDs in patients with common arthritis disorders: a meta-analysis. Eur J Rheum Inflamm. 1996;16(1):37-45.

19. Yanagawa A, Endo T, Kusakari K, et al. Endoscopic Evaluation of AceclofenacInduced Gastroduodenal Mucosal Damage: A Double-Blind Comparison with Sodium Diclofenac and Placebo. J Rheumatol. 1998; (8):249-59. doi: 10.3109/BF03041246/

20. Wassif W, Bjarnason I. A comparison of the effects of aceclofenac and diclofenac on gastrointestinal blood loss. Br J Clin Research. 1992;(3):109-11.

21. Pareek A, Chandurkar N. Comparison of gastrointestinal safety and tolerability of aceclofenac with diclofenac: a multicenter, randomized, double- blind study in patients with knee osteoarthritis. Curr Med Res Opin. 2013 Jul;29(7):849-59. doi: 10.1185/03007995.2013.795139.

22. Huskinsson EC, Irani M, Murray F. A large prospective open-label, multi-centre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur J Rheumatol Inflam. 2000;(17):1-7.

23. Llorente Melero MJ, Tenias Burillo JM, Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev Esp Enferm Dig. 2002 Jan; 94(1):7-18.

24. Helin-Salmivaara A, Virtanen A, Veslainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a national casecontrol study from Finland. Eur Heart J. 2006 Jul;27(14):1657-63. doi: 10.1093/eurheartj/ehl053. Epub 2006 May 26.

25. Legrand E. Aceclofenac in the management of inflammatory pain. Expert Opin Pharmacother. 2004 Jun;5(6):1347-57.

26. Vohra F, Raut A. Comparative efficacy, safety, and tolerability of diclofenac and aceclofenac in musculoskeletal pain management: A systematic review. Indian J Pain. 2016;(30):3-6. doi: 10.4103/0970-5333.173431.

27. Patel PB, Patel TK. Efficacy and safety of aceclofenac in osteoarthritis: A meta-analysis of randomized controlled trials. Eur J Rheumatol. 2017 Mar;4(1):11-8. doi: 10.5152/eurjrheum. 2017.160080.

28. Jung SY, Jang EJ, Nam SW, et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network metaanalysis. Mod Rheumatol. 2018 Nov;28(6):1021-28. doi: 10.1080/14397595.2018.1439694.

29. Lemmel EM, Leeb B, De Bast J, Aslanidis S. Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study (experience with aceclofenac for inflammatory pain in daily practice). Aceclofenac is the treatment of choice for patients and physicians in the management of inflammatory pain. Curr Med Res Opin. 2002;18(3):146-53. doi: 10.1185/030079902125000507.